Back to Search
Start Over
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
- Authors :
- Dimopoulos, M.A. Lonial, S. White, D. Moreau, P. Weisel, K. San-Miguel, J. Shpilberg, O. Grosicki, S. Špička, I. Walter-Croneck, A. Magen, H. Mateos, M.-V. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Orlowski, R.Z. Taniwaki, M. Röllig, C. Einsele, H. Matsumoto, M. Wu, K.L. Anderson, K.C. Jou, Y.-M. Ganetsky, A. Singhal, A.K. Richardson, P.G.
Dimopoulos, M.A. Lonial, S. White, D. Moreau, P. Weisel, K. San-Miguel, J. Shpilberg, O. Grosicki, S. Špička, I. Walter-Croneck, A. Magen, H. Mateos, M.-V. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Orlowski, R.Z. Taniwaki, M. Röllig, C. Einsele, H. Matsumoto, M. Wu, K.L. Anderson, K.C. Jou, Y.-M. Ganetsky, A. Singhal, A.K. Richardson, P.G.
- Publication Year :
- 2020
Details
- Database :
- OAIster
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1478880906
- Document Type :
- Electronic Resource